Navigation Links
StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie

LONDON, April 10, 2013 /PRNewswire/ --

The Dow Jones Index closed at an all time high at 14,673.46, up 0.41 percent while NASDAQ was up 0.48 percent to end yesterday's session at 3,237.86. Similarly, S&P also finished Tuesday's trading session on a positive note at 1,568.61, up 0.35 percent. The markets showed across the board improvement and a bullish trend. Our research team took a look at the Healthcare sector, focusing on the major drug makers industry which include including companies like Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and AbbVie Inc. (NYSE: ABBV). StockCall reviewed the Drug Manufacturers - Major industry and chose PFE, MRK, JNJ, and ABBV for its technical coverage. These free reports can be seen for free at

Pfizer Inc. is trading below its long-term moving average price, indicating a neutral trend. It also closed its latest trading session at $29.11, down 0.17 percent. The stock made its downward movement with below average volume of 27.53 million shares. Pfizer Inc. trades at Price/Earnings ratio of 23.10, in-line with industry average, making the stock a fairly priced proposition. However, the stock provided good return to its holders as it appreciated 16.95 percent this year. Pfizer's stock also gained 30.3 percent in the past 52 weeks, and it oscillated between $21.40 and $29.44 during this time period. Download the free research on PFE by signing up now at

Merck & Co. Inc. is currently trading in overbought territory with its Relative Strength Index at 70.18. Consequently, the stock may see some pullback in the coming sessions. It closed its Tuesday's session at $45.51, up 0.07 percent. The stock is currently in a bullish mode and may touch $45.67 level in the coming days. Upon breaching this level, the stock's next resistance price is at $47.96. the drug maker's stock has low volatility with its beta at 0.58. So far in 2013, the stock appreciated 11.98 percent. Its 52 weeks gain stands at 17.05 percent. The stock has traded in the range of $37.02 and $48 during the said time period. Register for today's free analysis on MRK at

Johnson & Johnson extended its 52 weeks gain by closing 0.51 percent higher. The stock ended Tuesday's session at $81.52, while its highest price point for the session stood at $81.75. It traded 9.08 million shares, down from its average daily volume of 9.98 million. Johnson & Johnson traded in the range of $61.71 and $82.95 in the past 52 weeks, and currently it is trading near its high price point. The company commands market capitalization of $228.01 billion and it reported its latest EPS at $3.86. Johnson & Johnson's stock gained more than 24 percent in the past 52 weeks. Free report on JNJ can be accessed by registering at

AbbVie Inc. traded up with above average volume to end its latest session at $42.55. The stock ended 1.87 percent higher than its previous close. Its volume for the day stood at 8.67 million shares. The stock is currently trading marginally lower than its 20-day SMA of $42.58 and its 50-day SMA of $42.77. Its first resistance level is at $42.87 while it may tumble down to $42.33 before receiving any support. AbbVie's stock is up 23.26 percent on a YTD basis, while offering 3.76 percent dividend yield. Register with StockCall and download the research on ABBV for free at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
2. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
3. Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
4. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
5. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
6. Merck Serono et lInstitut Feinstein vont sassocier pour développer un programme pré-clinique portant sur les maladies inflammatoires
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
11. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
Post Your Comments:
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), a ... solid tumor cancers, announced today that the Board is ... Company welcomes Neil Woodford,s call for an ... report on NW Bio.  The Company,s Board is under ... stated, "We agree with Mr. Woodford that, at NW ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/11/2015)... Nov. 11, 2015   MedNet Solutions , an innovative ... clinical research, is pleased to announce that it will be ... (PCT) event, to be held November 17-19 in ... view live demonstrations of iMedNet , MedNet,s ... iMedNet has been able to deliver time and ...
Breaking Biology News(10 mins):